Bayer Pharmaceuticals Corporation
Records under this name other than patents Bayer Pharmaceuticals Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Bayer Pharmaceuticals Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,612,925 | Double-Side Image Scanner and Scanning Method of the Same Formerly held In force · High confidence | In force | High confidence | |
| US 8,124,782 | Process for the Preparation of 4-{4-[({[4-Chloro-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-Carboxamide Formerly held In force · High confidence | In force | High confidence | |
| US 9,737,488 | Pharmaceutical Composition for the Treatment of Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,637,553 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,796,250 | Diaryl ureas for diseases mediated by PDGFR Formerly held In force · USPTO record | In force | USPTO record | |
| US 6,774,117 | MN gene and protein Formerly held Term ended Term ended Aug 10, 2026 · USPTO record | Term ended | Term ended Aug 10, 2026 | USPTO record |
| US 7,563,791 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis Formerly held Term ended Term ended Nov 1, 2025 · USPTO record | Term ended | Term ended Nov 1, 2025 | USPTO record |
| US RE46,856 | Substituted 2,3-Dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis Formerly held Lapsed on the fee record Ended Jun 18, 2025 · Low confidence | Lapsed on the fee record | Ended Jun 18, 2025 | Low confidence |
| US 7,951,588 | Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells Formerly held Term ended Term ended Feb 14, 2025 · High confidence | Term ended | Term ended Feb 14, 2025 | High confidence |
| US 7,511,041 | Fused Azole-Pyrimidine Derivatives Formerly held Term ended Term ended May 13, 2024 · High confidence | Term ended | Term ended May 13, 2024 | High confidence |